Modulators of DUX4 for Regulation of Muscle Function
AssigneeSonic Master Limited
InventorsAmanda Rickard, Anabel De La Garza, Uli Schmidt, Alexander Kiselyov
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases or disorders. In some cases, the methods and compositions involve the use of methyltransferase inhibitors to inhibit or repress DUX4 expression in muscle cells. Further disclosed herein are methods and cell-based assays for screening compounds for the treatment of facioscapulohumeral muscular dystrophy and other muscle diseases.
Claims26
1-42. (canceled)
A kit comprising:
- a) a pharmaceutical composition comprising a compound of Formula (I)
- or a pharmaceutically acceptable salt thereof, wherein:
- A is selected from C5-12 carbocycle and 5- to 12-membered heterocycle;
- B is selected from C5-12 carbocycle and 5- to 12-membered heterocycle;
- C is selected from bond, C5-12 carbocycle, and 5- to 12-membered heterocycle;
- D is selected from bond, C5-12 carbocycle, and 5- to 12-membered heterocycle;
- each of L1 and L2 is independently selected from bond,
- —O—, —S—, —N(R51)—, N(R51)CH2—,
- —C(O)—, —C(O)O—, —OC(O)—, —OC(O)02-,
- —C(O)N(R51)—, —C(O)N(R51)C(O)—, —C(O)N(R51)C(O)N(R51)—, —N(R51)C(O)—, —N(R51)C(O)N(R51)—, —N(R51)C(O)O—, —OC(O)N(R51)—,
- —C(NR51)—, —N(R51)C(NR51)—, —C(NR51)N(R51)—, —N(R51)C(NR51) N(R51)—, —S(O)2,
- —OS(O)—, —S(O)O—, —S(O)—, —OS(O)2—,
- —OS(O)2O—, —N(R51)S(O)2—, —S(O)2N(R51)—,
- —N(R51)S(O)—, —S(O)N(R51)—, —N(R51)S(O)2N(R51)—, and —N(R51)S(O)N(R51)— or from alkylene, alkenylene, alkynylene, heteroalkylene, heteroalk-enylene, and heteroalkynylene, each of which is optionally substituted with one or more R50,
- R50 is, at each occurrence, independently selected from:
- halogen, —NO2, —CN, —OR52, —SR52, —N(R52),
- —NR53R54, —S(═O)R52, —S(═O)2R52,
- —S(═O)2R522, —S(═O)2NR53R54, —NR52S(═O)2R52, —NR52S(═O)2N(R52)2, —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52, —OC(O)R52,
- —OC(O)OR52, —OC(O)N(R52)2, —OC(O)NR53R54, —NR52C(O)R52, —NR52C(O)OR52,
- —NR52C(O)N(R52)2, —NR52C(O)NR53R54,
- —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2,
- —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR52P(O)(R52), —P(O)(NR52)(OR52), —P(O)(NR52)2, ═O, ═S, ═N(R52);
- C1-10 alkyl, C1-10 alkenyl, and C2-10 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO2, —CN, —OR52, —SR52, —N(R52)2, —NR53R54, —S(═O)R52, —S(═O)2R52, —S(═O)N(R52)2, —S(═O)2NR53R54,
- —NR52S(═O)2R52, —NR52S(═O)2N(R52)2,
- —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52,
- —OC(O)R52, —OC(O)OR52, —OC(O)N(R52)2,
- —OC(O)N53R54, —NR52C(O)R52, —NR52C(O)OR52, —NR52C(O)N(R52)2, —NR52C(O)NR53R54,
- —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2,
- —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR52P(O)(R52), —P(O)(NR52)(OR52),
- —P(O)(NR52)2, ═O, ═S, ═N(R52) C3-12 carbocycle, and 3- to 12-membered heterocycle;
- and
- C3-12 carbocycle and 3- to 12-membered heterocycle, wherein each C3-12 carbocycle and 3- to 12-membered heterocycle in R50 is independently optionally substituted with one or more substituents selected from halogen, —NO2, —CN, —OR52, —SR52, —N(R52)2, —NR53R54, —S(═O)R52, —S(═O)2R52, —S(═O)2N(R52)2, —S(═O)2NR53R54, —NR52S(═O)2R52, —NR52S(═O)2N(R52)2, —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52, —OC(O)R52, —OC(O)OR52, —OC(O)N(R52)2, —OC(O)N53R54, —NR52C(O)R52, —NR52C(O)OR52, —NR52C(O)N(R52)2, —NR52C(O)NR53R54, —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2, —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR52P(O)(R52), —P(O)(NR52)(OR52), —P(O)(NR52)2, ═O, ═S, ═N(R52), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- R51 is independently selected at each occurrence from:
- hydrogen, —C(O) R52, —C(O)OR52, —C(O)N(R52)2, —C(O)NR53R54;
- C1-6 alkyl, C2-6 alkenyl, and C2-6 alkenyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO2, —CN, —OR52, —SR52, —N(R52)2, —NR53R54, —S(═O)R52, —S(═O)2R52, —S(═O)2N(R52)2, —S(═O)2NR53R54, —NR52S(═O)2R52, —NR52S(═O)2N(R52)2, —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52, —OC(O)R52, —OC(O)OR52, —OC(O)N(R52)2, —OC(O)N53R54, —NR52C(O)R52, —NR52C(O)OR52, —NR52C(O)N(R52)2, —NR52C(O)NR53R54, —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2, —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR52P(O)(R52), —P(O)(NR52)(OR52), —P(O)(NR52)2, ═O, ═S, ═N(R52), C3-12 carbocycle and 3- to 12-membered heterocycle;
- and
- C3-12 carbocycle and 3- to 12-membered heterocycle, wherein each C3-12 carbocycle and 3- to 12-membered heterocycle in R51 is independently optionally substituted with one or more substituents selected from halogen, —NO2, —CN, —OR52, —SR52, —N(R52)2, —NR53R54, —S(═O)R52, —S(═O)2R52, —S(═O)2N(R52)2, —S(═O)2NR53R54, —NR52S(═O)2R52, —NR52S(═O)2N(R52)2, —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52, —OC(O)R52, —OC(O)OR52, —OC(O)N(R52)2, —OC(O)N53R54, —NR52C(O)R52, —NR52C(O)OR52, —NR52C(O)N(R52)2, —NR52C(O)NR53R54, —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2, —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR52P(O)(R52), —P(O)(NR52)(OR52), —P(O)(NR52)2, ═O, ═S, ═N(R52), C1-6 alkyl, C1-6 haloalkyl, C1-6 alkenyl, and C2-6 alkynyl;
- R52 is independently selected at each occurrence from hydrogen;
- and C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, 1- to 6-membered heteroalkyl, C3-12 carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted by halogen, —CN, —NO2, —NH2, —NHCH3, —NHCH2CH3, ═O, —OH, —OCH3, —OCH2CH3, C3-12 carbocycle, or 3- to 6-membered heterocycle;
- R53 and R54 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R50;
- each of RA, RB and RC is independently selected from R50;
- RD is, at each occurrence, independently selected from hydrogen or R50;
- and
- each of m, n, p, and q is independently an integer from 0-12;
- and
- b) packaging materials.
A method of determining D4Z4 de-repression activity of a compound in a cell, comprising:
- administering a DNA methyltransferase inhibitor to the cell, thereby inducing DUX4 expression in the cell;
- administering a compound to the cell, wherein the compound is of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- A is selected from C5-12 carbocycle and 5- to 12-membered heterocycle;
- B is selected from C5-12 carbocycle and 5- to 12-membered heterocycle;
- C is selected from bond, C5-12 carbocycle, and 5- to 12-membered heterocycle;
- D is selected from bond, C5-12 carbocycle, and 5- to 12-membered heterocycle;
- each of L1 and L2 is independently selected from bond,
- —O—, —S—, —N(R51)—, N(R51)CH2—,
- —C(O)—, —C(O)O—, —OC(O)—, —OC(O)02-,
- —C(O)N(R51)—, —C(O)N(R51)C(O)—, —C(O)N(R51)C(O)N(R51)—, —N(R51)C(O)—, —N(R51)C(O)N(R51)—, —N(R51)C(O)O—, —OC(O)N(R51)—,
- —C(NR51)—, —N(R51)C(NR51)—, —C(NR51)N(R51)—, —N(R51)C(NR51) N(R51)—, —S(O)2,
- —OS(O)—, —SO(O)O—, —S(O)—, —OS(O)02-,
- —OS(O)2O—, —N(R51)S(O)2—, —S(O)2N(R51)—,
- —N(R51)S(O)—, —S(O)N(R51)—, —N(R51)S(O)2N(R51)—, and —N(R51)S(O)N(R51)— or from alkylene, alkenylene, alkynylene, heteroalkylene, heteroalk-enylene, and heteroalkynylene, each of which is optionally substituted with one or more R50;
- R50 is, at each occurrence, independently selected from:
- halogen, —NO2, —CN, —OR52, —SR52, —N(R52)2,
- —NR53R54, —S(═O)R52, —S(═O)2R52,
- —S(═O)2R522, —S(═O)2NR53R54, —NR52S(═O)2R52, —NR52S(═O)2N(R52)2, —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52, —OC(O)R52,
- —OC(O)OR52, —OC(O)N(R52)2, —OC(O)NR53R54, —NR52C(O)R52, —NR52C(O)OR52,
- —NR52C(O)N(R52)2, —NR52C(O)NR53R54,
- —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2,
- —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR52P(O)(R52), —P(O)(NR52)(OR52), —P(O)(NR52)2, ═O, ═S, ═N(R52);
- C1-10 alkyl, C1-10 alkenyl, and C2-10 alkynyl, each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO2, —CN, —OR52, —SR52, —N(R52), —NR53R54, —S(═O)R52, —S(═O)2R52, —S(═O)2N(R52)2, —S(═O)2NR53R54,
- —NR52S(═O)2R52, —NR52S(═O)2N(R52)2,
- —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52,
- —OC(O)R52, —OC(O)OR52, —OC(O)N(R52)2,
- —OC(O)N53R54, —NR52C(O)R52, —NR52C(O)OR52, —NR52C(O)N(R52)2, —NR52C(O)NR53R54,
- —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2,
- —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR52P(O)(R52), —P(O)(NR52)(OR52),
- —P(O)(NR52)2, ═O, ═S, ═N(R52), C3-12 carbocycle, and 3- to 12-membered heterocycle;
- and
- C3-12 carbocycle and 3- to 12-membered heterocycle, wherein each C3-12 carbocycle and 3- to 12-membered heterocycle in R50 is independently optionally substituted with one or more substituents selected from halogen —NO2, —CN, —OR52, —SR52, —N(R52), —NR53R54, —S(═O)R52, —S(═O)2R52, —S(═O)2N(R52)2, —S(═O)2NR53R54, —NR52S(═O)2R52, —NR52S(═O)2N(R52)2, —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52, —OC(O)R52, —OC(O)OR52, —OC(O)N(R52)2, —OC(O)N53R54, —NR52C(O)R52, —NR52C(O)OR52, —NR52C(O)N(R52)2, —NR52C(O)NR53R54, —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2, —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR52P(O)(R52), —P(O)(NR52)(OR52), —P(O)(NR52)2, ═O, ═S, ═N(R52), C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, and C2-6 alkynyl;
- R51 is independently selected at each occurrence from:
- hydrogen, —C(O) R52, —C(O)OR52, —C(O)N(R52)2, —C(O)NR53R54;
- C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl each of which is independently optionally substituted at each occurrence with one or more substituents selected from halogen, —NO2, —CN, —OR52, —SR52, —N(R52)2, —NR53R54, —S(═O)R52, —S(═O)2R52, —S(═O)2N(R52)2, —S(═O)2NR53R54, —NR52S(═O)2R52, —NR52S(═O)2N(R52)2, —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52, —OC(O)R52, —OC(O)OR52, —OC(O)N(R52)2, —OC(O)N53R54, —NR52C(O)R52, —NR52C(O)OR52, —NR52C(O)N(R52)2, —NR52C(O)NR53R54, —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2, —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR5—P(O)(R52), —P(O)(NR52)(OR52), —P(O)(NR52)2, ═O, ═S, ═N(R52), C3-12 carbocycle and 3- to 12-membered heterocycle;
- and
- C3-12 carbocycle and 3- to 12-membered heterocycle, wherein each C3-12 carbocycle and 3- to 12-membered heterocycle in R51 is independently optionally substituted with one or more substituents selected from halogen, —NO2, —CN, —OR52, —SR52, —N(R52), —NR53R54, —S(═O)R52, —S(═O)2R52, —S(═O)2N(R52)2, —S(═O)2NR53R54, —NR52S(═O)2R52, —NR52S(═O)2N(R52)2, —NR52S(═O)2NR53R54, —C(O)R52, —C(O)OR52, —OC(O)R52, —OC(O)OR52, —OC(O)N(R52)2, —OC(O)N53R54, —NR52C(O)R52, —NR52C(O)OR52, —NR52C(O)N(R52)2, —NR52C(O)NR53R54, —C(O)N(R52)2, —C(O)NR53R54, —P(O)(OR52)2, —P(O)(R52)2, —P(O)(OR52)(R52), —P(O)(NR52)(R52), —NR52P(O)(R52), —P(O)(NR52)(OR52), —P(O)(NR52)2, ═O, ═S, ═N(R52), C1-6 alkyl, C1-6 haloalkyl, C1-6 alkenyl, and C2-6 alkynyl;
- R52 is independently selected at each occurrence from hydrogen;
- and C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, 1- to 6-membered heteroalkyl, C3-12 carbocycle, and 3- to 12-membered heterocycle, each of which is optionally substituted by halogen, —CN, —NO2, —NH2, —NHCH3, —NHCH2CH3, ═O, —OH, —OCH3, —OCH2CH3, C3-12 carbocycle, or 3- to 6-membered heterocycle;
- R53 and R54 are taken together with the nitrogen atom to which they are attached to form a heterocycle, optionally substituted with one or more R50;
- each of RA, RB and RC is independently selected from R50;
- RD is, at each occurrence, independently selected from hydrogen or R50;
- and
- each of m, n, p, and q is independently an integer from 0-12;
- and
- measuring DUX4 expression, thereby determining D4Z4 de-repression activity of the compound in the cell.
49-52. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of reducing DUX4 expression in a subject, comprising:
- administering a histone methyltransferase inhibitor to the subject, thereby reducing expression of DUX4, wherein the subject has symptoms of facioscapulohumeral muscular dystrophy (FSHD).
Dependencies are inferred from the claim text.